Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10967970 | Vaccine | 2013 | 7 Pages |
Abstract
The first 6 months of life is a time of particularly increased influenza risk among young children, and an age group for which current vaccines are not approved. Previous studies have found that maternal influenza immunization can reduce acute respiratory infection in the infant during this vulnerable period. Additional randomized, controlled trials are currently underway using a vaccine probe approach to estimate VPDI among mothers and their infants following maternal influenza immunization. The World Health Organization now identifies pregnant women as the highest priority target group for influenza vaccination. Should countries implement this strategy, infants age 6-23 months likely would remain at increased risk; vaccine probe approaches could quantify the public health benefit of immunizing this group.
Keywords
QIVLAIVRSVTIVInfluenzaVaccine effectivenessImmunizationdisease burdenProgram for Appropriate Technology in HealthPathHaemophilus influenzae type bHibVaccinelive attenuated influenza vaccineTrivalent influenza vaccineRespiratory syncytial virushuman immunodeficiency virusHIVPerchClinical trialConference report
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Bradford D. Gessner, W. Abdullah Brooks, Kathleen M. Neuzil, Guy Vernet, Rick A. Bright, John S. Tam, Joseph Bresee, Arnold S. Monto,